NCT06223763 2024-01-25
SUROVA
Clinica Universidad de Navarra, Universidad de Navarra
Unknown
Clinical Trials
72 trialsNCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT05960630 2023-11-18
MIRRORS-RCTP
Royal Surrey County Hospital NHS Foundation Trust
Phase NA Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT03363867 2023-08-07
BEACON
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT05801783 2023-04-06
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05792254 2023-03-31
Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer
Ruijin Hospital
Phase NA Unknown
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT03430700 2023-01-30
PROMPT
University College, London
Phase 2 Unknown
NCT02125513 2022-12-30
GOGER-01
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Unknown
NCT05665023 2022-12-29
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Yonsei University
Phase 2 Unknown
NCT05622890 2022-11-21
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03540017 2022-11-02
HIPEC After Initial CRS in Patients Who Have Received NACT
Northwell Health
Phase 1 Unknown
NCT05537844 2022-09-23
BriTROC-2
Cancer Research UK, Glasgow
Unknown
NCT05043402 2022-08-15
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
OncXerna Theraputics, Inc.
Phase 3 Unknown
NCT02033616 2022-04-25
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Aivita Biomedical, Inc.
Phase 2 Unknown
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04295577 2022-01-21
MONITOR-UK
Royal Marsden NHS Foundation Trust
Unknown
NCT04375956 2021-12-20
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT00108745 2021-09-30
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 3 Unknown
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT01366183 2021-09-30
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
GOG Foundation
Unknown
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT04267575 2021-08-09
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Phase NA Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT01611766 2021-06-10
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Shanghai Gynecologic Oncology Group
Phase 3 Unknown
NCT04846842 2021-04-19
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT03000192 2021-03-17
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
University Hospital Southampton NHS Foundation Trust
Unknown
NCT04556071 2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04402333 2020-09-02
MIRRORS
Royal Surrey County Hospital NHS Foundation Trust
Unknown
NCT00652119 2020-08-19
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Massachusetts General Hospital
Phase 1 Unknown
NCT03150121 2020-02-26
BEDOCA
Sheba Medical Center
Phase NA Unknown
NCT00499512 2020-01-10
Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Unknown
NCT03693248 2019-12-10
ROCOCO
Seoul National University Hospital
Phase 3 Unknown
NCT03373058 2019-11-06
EHTASEOCCS
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT04001023 2019-08-07
OVANOX
Turku University Hospital
Phase NA Unknown
NCT04029909 2019-07-23
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 1 Unknown
NCT02349958 2019-04-16
HIPEC/IPHC
Bay Area Gynecology Oncology
Phase 2 Unknown
NCT00958698 2019-03-12
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase NA Unknown
NCT01372787 2019-03-12
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
GOG Foundation
Unknown
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT03283943 2018-07-11
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
British Columbia Cancer Agency
Phase 1 Unknown
NCT03188159 2018-03-29
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT00719303 2018-02-19
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Unknown
NCT02534922 2018-02-14
ProlantaOC
Oncolix, Inc.
Phase 1 Unknown
NCT03180177 2018-01-24
EHNPCTASEOC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown